Repositorio Institucional
Repositorio Institucional
CONICET Digital
  • Inicio
  • EXPLORAR
    • AUTORES
    • DISCIPLINAS
    • COMUNIDADES
  • Estadísticas
  • Novedades
    • Noticias
    • Boletines
  • Ayuda
    • General
    • Datos de investigación
  • Acerca de
    • CONICET Digital
    • Equipo
    • Red Federal
  • Contacto
JavaScript is disabled for your browser. Some features of this site may not work without it.
  • INFORMACIÓN GENERAL
  • RESUMEN
  • ESTADISTICAS
 
Artículo

Low doses of CPS49 and flavopiridol combination as potential treatment for advanced prostate cancer

Zalazar, FlorenciaIcon ; de Luca, PaolaIcon ; Gardner, Kevin; Figg, William D.; Meiss, Roberto; Spallanzani, Raúl GermánIcon ; Vallecorsa, Pablo DanielIcon ; Elguero, María BelénIcon ; Cotignola, Javier HernanIcon ; Vazquez, Elba SusanaIcon ; de Siervi, AdrianaIcon
Fecha de publicación: 01/2015
Editorial: Bentham Science Publishers
Revista: Current Pharmaceutical Biotechnology
ISSN: 1389-2010
e-ISSN: 1873-4316
Idioma: Inglés
Tipo de recurso: Artículo publicado
Clasificación temática:
Farmacología y Farmacia

Resumen

Prostate cancer (PCa) still ranks as the second most frequently diagnosed cancer and metastatic castrationresistantprostate cancer (CRPC) is a foremost cause of men cancer death around the world. The aim of this work was toinvestigate the selectivity and efficacy of new drug combinations for CRPC. We combined three compounds: paclitaxel(PTX: taxane that inhibits microtubule polymerization); 2-(2,4-Difluoro-phenyl)-4,5,6,7-tetrafluoro-1H-isoindole-1,3(2H)-dione (CPS49; redox-reactive thalidomide analog with anti-angiogenic properties) and flavopiridol (flavo: semisyntheticflavonoid that inhibits cyclin dependent kinases). We assessed CPS49-flavo or -PTX combinations cytotoxicityin a panel of PCa cell lines and PC3 xenografts. We found that CPS49 enhanced flavo or PTX cytotoxicity in human PCacell lines while showed resistance in a non-tumor cell line. Furthermore, xenografts generated by inoculation of humanprostate carcinoma PC3 cells in nu/nu mice showed that CPS49/flavo administration reduced tumor growth both after 2weeks of co-treatment and after 1 week of pretreatment with a low dose of flavo followed by 2 weeks of co-treatment.PTX and CPS49 combination did not significantly reduce tumor growth in PC3 xenografts. Histological analysis ofxenograft PC3 tumor samples from CPS49/flavo combination showed extensive areas of necrosis induced by the treatment.RT-qPCR array containing 23 genes from PC3 cells or PC3 xenografts exposed to CPS49/flavo combinationshowed that this treatment shut down the expression of several genes involved in adhesion, migration or invasion. Insummary, the antitumor activity of CPS49 or flavopiridol was improved by the combination of these compounds and usinghalf dose of that previously reported. Hence, CPS49-flavo combination is a promising new alternative for PCa therapy.
Palabras clave: Cps49 , Flavopiridol , Paclitaxel , Preclinical Study , Prostate Cancer , Xenografts
Ver el registro completo
 
Archivos asociados
Thumbnail
 
Tamaño: 1.181Mb
Formato: PDF
.
Descargar
Licencia
info:eu-repo/semantics/openAccess Excepto donde se diga explícitamente, este item se publica bajo la siguiente descripción: Creative Commons Attribution-NonCommercial-ShareAlike 2.5 Unported (CC BY-NC-SA 2.5)
Identificadores
URI: http://hdl.handle.net/11336/51594
URL: http://www.eurekaselect.com/130132/article
DOI: http://dx.doi.org/10.2174/138920101606150407114407
Colecciones
Articulos(IQUIBICEN)
Articulos de INSTITUTO DE QUIMICA BIOLOGICA DE LA FACULTAD DE CS. EXACTAS Y NATURALES
Citación
Zalazar, Florencia; de Luca, Paola; Gardner, Kevin; Figg, William D.; Meiss, Roberto; et al.; Low doses of CPS49 and flavopiridol combination as potential treatment for advanced prostate cancer; Bentham Science Publishers; Current Pharmaceutical Biotechnology; 16; 6; 1-2015; 553-563
Compartir
Altmétricas
 

Enviar por e-mail
Separar cada destinatario (hasta 5) con punto y coma.
  • Facebook
  • X Conicet Digital
  • Instagram
  • YouTube
  • Sound Cloud
  • LinkedIn

Los contenidos del CONICET están licenciados bajo Creative Commons Reconocimiento 2.5 Argentina License

https://www.conicet.gov.ar/ - CONICET

Inicio

Explorar

  • Autores
  • Disciplinas
  • Comunidades

Estadísticas

Novedades

  • Noticias
  • Boletines

Ayuda

Acerca de

  • CONICET Digital
  • Equipo
  • Red Federal

Contacto

Godoy Cruz 2290 (C1425FQB) CABA – República Argentina – Tel: +5411 4899-5400 repositorio@conicet.gov.ar
TÉRMINOS Y CONDICIONES